Tennessee is currently home to 1922 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
Recruiting
The objective of this clinical study is to compare OSTEOAMP SELECT Fibers to Infuse Bone Graft, in terms of effectiveness and safety, when used as a bone graft substitute in in skeletally mature patients qualified for 2-lumbar interbody fusion (LIF) by means of an intra-patient control model.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/25/2023
Locations: Tennessee Orthopaedic Alliance, Nashville, Tennessee
Conditions: Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: West Clinic, Germantown, Tennessee
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
Total Shoulder Arthroplasty Multi-Center Registry
Recruiting
The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/27/2023
Locations: Not set, Germantown, Tennessee
Conditions: Shoulder Arthroplasty
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? 2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Recruiting
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
Conditions: Systemic Amyloidosis
Evaluate the Continued Safety and Performance of the Foot and Ankle Products
Recruiting
The objective of the registry is to evaluate the continued safety and performance of the Arthrex foot and ankle products including the ProStop implant for hyperpronated foot, Bio-Compression Screw for reconstruction surgeries of the foot, TRIM-IT Drill Pin, TRIM-IT Spin Pin for fixation of fractures and fusion (bunionectomy osteotomies) of the foot/ankle, Headless Compression Screws and Compression FT Screws for fixation of small bone fragments of the foot/ankle and DynaNite® Nitinol Staple to b... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/26/2023
Locations: TOA Research Foundation, Nashville, Tennessee
Conditions: Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.)
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Recruiting
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test nove... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2023
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: MDS/MPN
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2023
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-007 - Urology Associates, P. C, Nashville, Tennessee
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Langerhans Cell Histiocytosis
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Recruiting
Proton therapy is a limited medical resource that is more expensive than conventional x-ray therapy. To correctly measure the success of proton therapy in treating different conditions, it is important to check a patient's health status after their treatment is finished. Checking on the progress of patients over many years (called long-term follow-up) is needed because the long-term effects of proton therapy are not well known.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2023
Locations: Provision CARES Proton Therapy Nashville, Franklin, Tennessee
Conditions: Cancer